Esophageal Adenocarcinoma

Curated

in context · predicts response to

AURKA Amplificationamplification → predicts response to Cisplatin

sensitivity

Curated

Esophageal Adenocarcinoma associated with …ASSOCIATED_WITH1 of 1
← associated with	AURKA	supports	E	Esophageal Adenocarcinoma	1	Curated	civic	graph →

Esophageal Adenocarcinoma associated with …ASSOCIATED_WITH1 of 1

← associated with

AURKA

supports

Curated

Esophageal Adenocarcinoma investigated for …INVESTIGATED_FOR2 of 2
← investigated for	Alisertibsmall_molecule	supports	E	Esophageal Adenocarcinoma	1	Curated	civic	graph →
← investigated for	Cisplatinsmall_molecule	supports	E	Esophageal Adenocarcinoma	1	Curated	civic	graph →

Esophageal Adenocarcinoma investigated for …INVESTIGATED_FOR2 of 2

← investigated for

Alisertibsmall_molecule

supports

Curated

← investigated for

Cisplatinsmall_molecule

supports

Curated

Esophageal Adenocarcinoma altered in cohorts of …ALTERED_INderived42 of 42show fewer
← altered in cohorts of	TP53 156 / 185 cases (84 %) · ssm · esca_tcga_gdc · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	TTN 97 / 185 cases (52 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	MUC16 51 / 185 cases (28 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	SYNE1 44 / 185 cases (24 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	CSMD3 40 / 185 cases (22 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	DNAH5 35 / 185 cases (19 %) · ssm · esca_tcga · largest of 3 cohorts	—	—	Esophageal Adenocarcinoma	3	Observed	cbioportal	graph →
← altered in cohorts of	HMCN1 34 / 185 cases (18 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	LRP1B 33 / 185 cases (18 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	FLG 32 / 185 cases (17 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	KMT2D 32 / 185 cases (17 %) · ssm · esca_tcga · largest of 3 cohorts	—	—	Esophageal Adenocarcinoma	3	Observed	cbioportal	graph →
← altered in cohorts of	RYR2 31 / 185 cases (17 %) · ssm · esca_tcga · largest of 3 cohorts	—	—	Esophageal Adenocarcinoma	3	Observed	cbioportal	graph →
← altered in cohorts of	MUC4 29 / 185 cases (16 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PCLO 29 / 185 cases (16 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	USH2A 29 / 185 cases (16 %) · ssm · esca_tcga · largest of 2 cohorts	—	—	Esophageal Adenocarcinoma	2	Observed	cbioportal	graph →
← altered in cohorts of	CSMD1 27 / 185 cases (15 %) · ssm · esca_tcga · largest of 4 cohorts	—	—	Esophageal Adenocarcinoma	4	Observed	cbioportal	graph →
← altered in cohorts of	OBSCN 27 / 185 cases (15 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CNTN6 22 / 151 cases (15 %) · ssm · esca_broad	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PTPRD 22 / 151 cases (15 %) · ssm · esca_broad	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PKHD1L1 26 / 185 cases (14 %) · ssm · esca_tcga · largest of 2 cohorts	—	—	Esophageal Adenocarcinoma	2	Observed	cbioportal	graph →
← altered in cohorts of	LAMA1 21 / 151 cases (14 %) · ssm · esca_broad	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	FAT3 25 / 185 cases (14 %) · ssm · esca_tcga · largest of 3 cohorts	—	—	Esophageal Adenocarcinoma	3	Observed	cbioportal	graph →
← altered in cohorts of	FAT4 25 / 185 cases (14 %) · ssm · esca_tcga · largest of 2 cohorts	—	—	Esophageal Adenocarcinoma	2	Observed	cbioportal	graph →
← altered in cohorts of	SPTA1 25 / 185 cases (14 %) · ssm · esca_tcga · largest of 3 cohorts	—	—	Esophageal Adenocarcinoma	3	Observed	cbioportal	graph →
← altered in cohorts of	APOB 20 / 151 cases (13 %) · ssm · esca_broad	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	MUC12 24 / 185 cases (13 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	DYNC2H1 23 / 185 cases (12 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	RYR3 23 / 185 cases (12 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	XIRP2 23 / 185 cases (12 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ADGRV1 22 / 185 cases (12 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	DST 22 / 185 cases (12 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	ATM 21 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	CDKN2A 21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts	—	—	Esophageal Adenocarcinoma	2	Observed	cbioportal	graph →
← altered in cohorts of	EYS 21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts	—	—	Esophageal Adenocarcinoma	2	Observed	cbioportal	graph →
← altered in cohorts of	NEB 21 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	PCDH15 21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts	—	—	Esophageal Adenocarcinoma	2	Observed	cbioportal	graph →
← altered in cohorts of	UNC13C 21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts	—	—	Esophageal Adenocarcinoma	2	Observed	cbioportal	graph →
← altered in cohorts of	ZNF804B 21 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	COL11A1 20 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	LRRK2 20 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	MUC17 20 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	NBEA 20 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →
← altered in cohorts of	SYNE2 20 / 185 cases (11 %) · ssm · esca_tcga	—	—	Esophageal Adenocarcinoma	1	Observed	cbioportal	graph →

Esophageal Adenocarcinoma altered in cohorts of …ALTERED_INderived42 of 42show fewer

← altered in cohorts of

TP53

156 / 185 cases (84 %) · ssm · esca_tcga_gdc · largest of 4 cohorts

—

Observed

← altered in cohorts of

TTN

97 / 185 cases (52 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

MUC16

51 / 185 cases (28 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

SYNE1

44 / 185 cases (24 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

CSMD3

40 / 185 cases (22 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

DNAH5

35 / 185 cases (19 %) · ssm · esca_tcga · largest of 3 cohorts

—

Observed

← altered in cohorts of

HMCN1

34 / 185 cases (18 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

LRP1B

33 / 185 cases (18 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

FLG

32 / 185 cases (17 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

KMT2D

32 / 185 cases (17 %) · ssm · esca_tcga · largest of 3 cohorts

—

Observed

← altered in cohorts of

RYR2

31 / 185 cases (17 %) · ssm · esca_tcga · largest of 3 cohorts

—

Observed

← altered in cohorts of

MUC4

29 / 185 cases (16 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

PCLO

29 / 185 cases (16 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

USH2A

29 / 185 cases (16 %) · ssm · esca_tcga · largest of 2 cohorts

—

Observed

← altered in cohorts of

CSMD1

27 / 185 cases (15 %) · ssm · esca_tcga · largest of 4 cohorts

—

Observed

← altered in cohorts of

OBSCN

27 / 185 cases (15 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

CNTN6

22 / 151 cases (15 %) · ssm · esca_broad

—

Observed

← altered in cohorts of

PTPRD

22 / 151 cases (15 %) · ssm · esca_broad

—

Observed

← altered in cohorts of

PKHD1L1

26 / 185 cases (14 %) · ssm · esca_tcga · largest of 2 cohorts

—

Observed

← altered in cohorts of

LAMA1

21 / 151 cases (14 %) · ssm · esca_broad

—

Observed

← altered in cohorts of

FAT3

25 / 185 cases (14 %) · ssm · esca_tcga · largest of 3 cohorts

—

Observed

← altered in cohorts of

FAT4

25 / 185 cases (14 %) · ssm · esca_tcga · largest of 2 cohorts

—

Observed

← altered in cohorts of

SPTA1

25 / 185 cases (14 %) · ssm · esca_tcga · largest of 3 cohorts

—

Observed

← altered in cohorts of

APOB

20 / 151 cases (13 %) · ssm · esca_broad

—

Observed

← altered in cohorts of

MUC12

24 / 185 cases (13 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

DYNC2H1

23 / 185 cases (12 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

RYR3

23 / 185 cases (12 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

XIRP2

23 / 185 cases (12 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

ADGRV1

22 / 185 cases (12 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

DST

22 / 185 cases (12 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

ATM

21 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

CDKN2A

21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts

—

Observed

← altered in cohorts of

EYS

21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts

—

Observed

← altered in cohorts of

NEB

21 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

PCDH15

21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts

—

Observed

← altered in cohorts of

UNC13C

21 / 185 cases (11 %) · ssm · esca_tcga · largest of 2 cohorts

—

Observed

← altered in cohorts of

ZNF804B

21 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

COL11A1

20 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

LRRK2

20 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

MUC17

20 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

NBEA

20 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

← altered in cohorts of

SYNE2

20 / 185 cases (11 %) · ssm · esca_tcga

—

Observed

Esophageal Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 51show all (up to 200)
→ investigated in trials for	Fluorouracilsmall molecule 25 trials (8 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 24 trials (10 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 18 trials (7 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 18 trials (11 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 12 trials (6 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 12 trials (5 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 11 trials (10 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 10 trials (9 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall_molecule 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumabmonoclonal antibody 7 trials (4 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Ramucirumabmonoclonal antibody 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Tremelimumabmonoclonal antibody 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Esophageal Adenocarcinoma	5	Observed	clinicaltrials	graph →

Esophageal Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 51show all (up to 200)

→ investigated in trials for

Fluorouracilsmall molecule

25 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

24 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Leucovorinsmall molecule

18 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

18 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

12 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

12 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

11 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall molecule

10 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cisplatinsmall_molecule

9 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trastuzumabmonoclonal antibody

7 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Irinotecansmall molecule

6 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ramucirumabmonoclonal antibody

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tremelimumabmonoclonal antibody

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

Esophageal Adenocarcinoma studied in …STUDIED_INderived10 of 181show all (up to 200)
→ studied in	NCT06324357Phase 1/Phase 2 · recruiting Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06203600Phase 2/Phase 3 · recruiting Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07212491enrolling by invitation Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07603375Phase 2 · recruiting Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05965999recruiting Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07277413Phase 1 · recruiting A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ALIAS · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07392892Phase 2/Phase 3 · recruiting Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06005493Phase 1/Phase 2 · recruiting Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152147Phase 3 · active not recruiting A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04295811NA · active not recruiting Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →

Esophageal Adenocarcinoma studied in …STUDIED_INderived10 of 181show all (up to 200)

→ studied in

NCT06324357Phase 1/Phase 2 · recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT06203600Phase 2/Phase 3 · recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · condition mapped CURATED_BROADER · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT07212491enrolling by invitation

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT07603375Phase 2 · recruiting

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT05965999recruiting

Lucid Registry Study · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT07277413Phase 1 · recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · condition mapped ALIAS · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT07392892Phase 2/Phase 3 · recruiting

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT06005493Phase 1/Phase 2 · recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT05152147Phase 3 · active not recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed

→ studied in

NCT04295811NA · active not recruiting

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC · condition mapped ONTOLOGY_EXACT · 181 trials mapped (84 active)

—

Observed